Vanguard Capital Management’s Faeth Therapeutics FTH Stock Holding History
Bought
Maintained
Sold
Other funds holding FTH
BBA
Vanguard Capital Management's FTH Position: Q3 2026 in Review
Vanguard Capital Management increased its Faeth Therapeutics (FTH) stake by 9,309% in Q3 2026, buying an estimated $29.3M and bringing the position to 951,721 shares worth $28.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2210.
Vanguard Capital Management first reported a position in FTH in Q1 2026 and has held it in 3 quarters since. 78 funds tracked by Wall St. Rank hold FTH as of Q3 2026.
- Vanguard Capital Management held 951,721 shares of Faeth Therapeutics worth $28.3M as of Q3 2026.
- Vanguard Capital Management bought 941,606 Faeth Therapeutics shares in Q3 2026, an estimated $29.3M.
- Faeth Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2210 holding.
- Vanguard Capital Management first reported a position in Faeth Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 78 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.